Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2003-08-21
2008-10-28
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C435S069400, C435S069700, C424S192100, C424S194100, C424S198100, C530S398000, C530S397000
Reexamination Certificate
active
07442376
ABSTRACT:
Forms of differentially acting glycoprotein hormones are disclosed. These compositions are of the formulain-line-formulae description="In-line Formulae" end="lead"?β1-(linker1)m-α-(linker2)n-β2; (1)in-line-formulae description="In-line Formulae" end="tail"?in-line-formulae description="In-line Formulae" end="lead"?β1-(linker1)m-β2-(linker2)n-α; (2)in-line-formulae description="In-line Formulae" end="tail"?in-line-formulae description="In-line Formulae" end="lead"?α-(linker1)m-β1-(linker2)n-β2; (3)in-line-formulae description="In-line Formulae" end="tail"?in-line-formulae description="In-line Formulae" end="lead"?β2≈α-(linker)m-β1; or (4)in-line-formulae description="In-line Formulae" end="tail"?in-line-formulae description="In-line Formulae" end="lead"?β1-(linker)m-α≈β2 (5)in-line-formulae description="In-line Formulae" end="tail"?wherein each of β1and β2has the amino acid sequence of the β subunit of a vertebrate glycoprotein hormone or a variant of said amino acid sequence, as variants are defined herein. “α” designates the α subunit of a vertebrate glycoprotein hormone or a variant thereof, “linker” refers to a covalently linked moiety that spaces the β1and β2subunits at appropriate distances from the α subunit and from each other. “≈” is a noncovalent link. Each of m and n is independently 0 or 1.
REFERENCES:
patent: 5338835 (1994-08-01), Boime
patent: 5420247 (1995-05-01), Gearing et al.
patent: 5705484 (1998-01-01), Thomason
patent: 0 163 406 (1985-12-01), None
patent: 0 839 831 (1998-05-01), None
patent: WO 85/01959 (1985-05-01), None
patent: WO 90/09800 (1990-09-01), None
patent: WO 91/16922 (1991-11-01), None
patent: WO 92 22568 (1992-12-01), None
patent: WO 95/22340 (1995-08-01), None
patent: WO 96/05224 (1996-02-01), None
patent: WO 99/25849 (1999-05-01), None
Duijkers, I J et al., “Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. I. Comparison of an FSH dominant and a purified FSH preparation.” International journal of fertility and women's medicine (US) Sep. Oct. 1997, 42 (5) p.306 10(Abstract only).
R.K. Hyde et al., Biology of Reproduction 54(Suppl. 1) :105, Abstract 193, 1996.
D. Ben-Menahem et al., Abstract OR28-3 presented at Endo 98, Endocrine Society, 1998.
G. De Rosa et al., Annales d'endocrinologie 48(6):468-472, 1987(Abstract only).
T. Sugahara et al., PNAS 92:2041-2045, 1995.
Bielinska,J Cell Biol(1990) 111:330a (Abstract 1844).
Boime et al., “Synthesis of Genetically Fused Single Chain Analog of Human Chorionic Gonadotropin: Implications for Drug Design and Structure-Function Relationships,”Proceeding of the Symposium: “The Ovary Regulation, Dysfunction and Treatment,” 1106:25-27 (1996).
Campbell et al., “Conversion of Human Choriogonadotropin into a Follitropin by Protein Engineering”,Proc Natl Acad Sci(1991) 88:760-764.
Chen and Okayama, “High-Efficiency Transformation of Mammalian Cells by Plasmid DNA”,Mol Cell Biol(1987) 7:2745-2752.
Chen et al., “The Carboxy-Terminal Region of the Glycoprotein Hormone α-Subunit: Contributions to Receptor Binding and Signaling in Human Chorionic Gonadotropin”Molec Endocrinol(1992) 6:914-919.
Dayhoff et al., “A Model of Evolutionary Change in Proteins”Atlas of Protein Sequences and Structure(1972) 5:89-99.
Duijkers et al., “Follicular Fluid Hormone Concentrations After Ovarian Stimulation Using Gonadotropin Preparations with Different FSH/LH ratios. 1. Comparison of an FSH-Dominant and a Purified FSH Preparation,”International Journal of Fertility and Women's Medicine(USA) 42(5):306-310 (1997) [abstract only].
Erickson et al., “Synthetic α-Subunit Peptides Stimulate Testosterone Production in Vitro by Rat Leydig Cells”Endocrinology(1990) 126:2555-2560.
Fares, “Design of a Long Acting Follitropin Agonist by Fusing the C-terminal Sequence of the Chorionic Gonadotropin ∃ Subunit to the Follitropin”Proc Natl Acad Sci USA(1992) 89:4304-4308.
Keutmann, “Receptor Binding Regions of hLH and hCG∃-Subunit: Structural and Functional Properties” pp. 103-117, 1993.
LaPolt, “Enhanced Stimulation of Follicle Maturation and Ovulatory Potential by Long Acting Follicle-Stimulating Hormone Agonists with Extended Carboxyl-Terminal Peptides”,Endocrinology(1992) 131:2514-2520.
Lapthorn, “Crystal Structure of Human Chorionic Gonadotropin”Nature(1994) 369:455-461.
Lustbader et al., EDS,Springer Verlag(New York) (1994) 122-134.
Matzuk et al., “Effects of Preventing O-glycosylation on the Secretion of Human Chorionic Gonadotropin in Chinese Hamster Ovary Cells”,Proc Natl Acad USA(1987) 84:6354-6358.
Matzuk et al., “The Glycoprotein α-Subunit is Critical for Secretion and Stability of the Human Thyrotropin ∃-Subunit”Mol Endocrinol(1988) 2:95-100.
Matzuk and Boime, “The Role of the Asparagine-linked Oligosaccharides of the α Subunit in the Secretion and Assembly of Human Chorionic Gonadotropin” J Cell Biol (1988) 106:1049-1059.
Moyle et al., “Co-Evolution of Ligand-Receptor Paris”Nature(1994) 368:251-255.
Patel, “A Clasped Embrace”Nature369:438-439, 1995.
Sachais et al., “Molecular Basis for the Species Selectivity of the Substance P Antagonist CP-96, 345” Biol Chem (1993) 268:2319.
Wu, H., “Structure of Human Chorionic Gonadotropin at 2.6 A Resolution from MAD analysis of the Selenomethionyl Protein”Structure(1994) 2:545-558.
Xiao-Chi et al., “Expression of Human Luteinizing Hormone (LH) and Chorionic Gonadotropin from Human but not Equine, Rat and Ovine Species” Endocrinol (1991) 5:759-768.
Yoo et al., “Conversion of Lysine 91 to Methionine or Glutamic Acid in Human Choriogonadotropin α Results in the Loss of cAMP Inducibility”J Biol Chem(1991) 266:17741-17743.
Ben-Menahem David
Boime Irving
Morrison & Foerster / LLP
Spector Lorraine
Washington University
LandOfFree
Glycoprotein hormone compositions containing two β... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycoprotein hormone compositions containing two β..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycoprotein hormone compositions containing two β... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001190